Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Covid-19 in liver transplant recipients: the French SOT COVID registry

Jérôme Dumortier a,*, Christophe Duvoux b, Olivier Roux c, Mario Altieri d, Hélène Barraud e, Camille Besch f, Sophie Caillard g, Audrey Coilly h, Filomena Conti i, Sébastien Dharancy j, François Durand c, Claire Francoz c, Florentine Garaix k, Pauline Houssel-Debr y l, Ilias Kounis h, Guillaume Lassailly j, Noémie Laverdure m, Vincent Leroy b, Maxime Mallet i, Alessandra Mazzola i, Lucy Meunier n, Sylvie Radenne o, Jean-Philippe Richardet b, Claire Vanlemmens b, Marc Hazzan q, Faouzi Saliba h, for the French Solid Organ Transplant COVID Registry the Groupe de Recherche Français en Greffe de Foie (GReF2),

a Hospices Civils de Lyon, Hôpital Edouard Herriot,Unité de Transplantation Hépatique et Université Claude Bernard Lyon 1, Lyon, France
b APHP, Hôpital Henri Mondor, Service d’Hépatologie, Créteil, France
c APHP, Hôpital Beaujon, Service d’Hépatologie et Transplantation Hépatique - Université Paris Diderot - INSERM U1149, Clichy, France
d Hôpital Côte de Nacre, Service d’Hépato-Gastroentérologie, Nutrition et Oncologie Digestive, Caen, France
e CHU Tours, Hôpital Trousseau Service de Chirurgie Digestive, Oncologique et Endocrinienne, Transplantation Hépatique, Tours, France
f CHRU Hautepierre, Service de Chirurgie Hépato-Bilio-Pancréatique et Transplantation Hépatique, Strasbourg, France
g CHRU Hautepierre, Service de Néphrologie et Transplantation et INSERM, IRM UMR-S 1109, Strasbourg, France
h AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, INSERM, Unité 1193, Villejuif, France
i AP-HP – Hôpital de la Pitié Salpêtrière, Service d’Hépatologie et Transplantation Hépatique, Paris, France
j CHRU Lille, Hôpital Claude Huriez, Service des Maladies de l’appareil Digestif et Université de Lille, Lille, France

The French SOT COVID Registry was approved by the Institutional Review Board of the Strasbourg University (approval number 02.26) and registered at clinicaltrials.gov (NCT04360707).

* Corresponding author.
E-mail address: jerome.dumortier@chu-lyon.fr (J. Dumortier).

https://doi.org/10.1016/j.clinre.2021.101639
2210-7401/© 2021 Elsevier Masson SAS. All rights reserved.
KEYWORDS
Covid-19;
Liver transplantation;
Immunosuppression;
Prognosis;
Mortality

Abstract

Background: Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in organ transplant recipients remains limited. The aim of this registry-based observational study was to report the characteristics and clinical outcomes of liver transplant (LT) recipients included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19.

Methods: COVID-19 was diagnosed in patients who had a positive PCR assay for SARS-CoV-2 or in presence of typical lung lesions on imaging or specific SARS-CoV-2 antibodies. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded.

Results: Of the 104 patients, 67 were admitted to hospital and 37 were managed at home (including all 13 children). Hospitalized patients had a median age of 65.2 years (IQR: 58.1 – 73.2 years) and two thirds were men. Most common comorbidities included overweight (67.3%), hypertension (61.2%), diabetes (50.7%), cardiovascular disease (20.9%) and respiratory disease (16.4%). SARS-CoV-2 infection was identified after a median of 92.8 months (IQR: 40.1 – 194.7 months) from LT. During hospitalization, antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively. The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients. The 30-day mortality rate was 20.0%, and 28.1% for hospitalized patients. Multivariate analysis identified that age was independently associated with mortality.

Conclusion: In our large nationwide study, Covid-19 in LT recipients was associated with a high mortality rate.

© 2021 Elsevier Masson SAS. All rights reserved.

Introduction

Coronavirus disease-2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an ongoing global pandemic of major concern. As of July 7, 2020, a total of 168,810 confirmed cases of Covid-19 occurred in France, of whom 29,933 died; Covid-19-related hospitalization totaled 105,048, of which 18,413 were intensive care unit (ICU) admissions. Patients with comorbidities are at high risk of developing severe disease. This includes solid organ transplant recipients [1], who are well known to be at increased risk for infectious complications, among which community-acquired respiratory viruses are unique due to the frequent exposure [2]. For instance, despite the availability of effective vaccines, severe influenza, requiring ICU-level care (11%) or mechanical ventilation (8%), can occur in solid organ transplant recipients, leading to 2%–4% mortality [3,4].

Available data on clinical presentation and prognosis in liver transplant (LT) recipients under immunosuppressive therapy remains limited [5–11]. On March 1, 2020, a French nationwide registry of patients with Covid-19 and history of solid organ transplantation has been established under the auspices of the French Speaking Society of Transplantation. As of July 7, 2020, a total of 696 patients were included in the registry, of whom 492 were kidney transplant (KT) recipients, 104 LT recipients, 61 heart transplant recipients, and 39 lung transplant recipients. Here, we describe the disease presentation, immunosuppression management, clinical outcomes, and prognostic factors in 104 LT recipients with Covid-19.

Patients and methods

Patients

Data from all French patients with Covid-19 and a history of LT included in a nationwide registry, termed French SOT COVID, between March 4 and July 1, 2020, were retrieved.
Patients who received double solid organ transplantation (liver with kidney, lung, or heart) were deemed eligible. The diagnostic criteria for Covid-19 were as follows: (1) evidence of SARS-CoV-2 infection on reverse transcriptase-polymerase chain reaction (RT-PCR) testing performed on nasopharyngeal swab specimens or (2) presence of typical respiratory symptoms accompanied by evocative pulmonary lesions on low-dose chest computed tomography (CT) and detection of specific antibodies against SARS-CoV-2 (in case of RT-PCR yielded negative results). Clinical and laboratory variables were extracted from medical records. In case of hospitalization, data on presentation and other clinical variables (including ongoing immunosuppressive therapy) were collected on admission. Changes in immunosuppression during the course of hospitalization were thoroughly recorded. Patients were divided into two groups according to their need for hospitalization (admitted to hospital versus managed at home). Severe COVID-19 was defined as admission (or transfer) to an intensive care unit (ICU), need for mechanical ventilation (MV), or death. All other patients were considered non-severe cases. The creation of the French SOT COVID Registry was approved by the Institutional Review Board of the Strasbourg University (approval number 02.26) and registered at clinicaltrials.gov (NCT04360707). The need for informed consent was waived; however, all patients were informed about their inclusion in the registry.

Statistical analysis

Categorical data are presented as counts and percentages. Continuous variables are expressed as medians and interquartile ranges (IQRs) upon verification of their skewed distribution with the Shapiro–Wilks test. Two time-dependent variables served as the outcome measures. The first was a composite endpoint of severe Covid-19 (including admission/transfer to an ICU, need for MV, or death), whereas the second was a hard end point consisting of death only. Survival curves were plotted with the Kaplan–Meier method and compared with the log-rank test. Cox proportional hazard univariate and multivariate models were constructed to identify predictors of the study endpoints. All variables showing an association with a P < 0.1 in univariate analysis were included as covariates in the multivariate model using a backward conditional selection procedure. The optimal model was selected according to the highest concordance value. Results are expressed as hazard ratios (HRs) with their 95% confidence intervals. All analyses were conducted in the R environment (R Foundation for Statistical Computing, Vienna, Austria), and two-tailed p values <0.05 were considered statistically significant.

Results

Patient characteristics

Study population consisted in 104 LT recipients: 91 adults and 13 children. The median follow-up time was 92 days, and none of the hospitalized patients were still in ICU at last follow-up. The first of our case was diagnosed on March the 1st and the last one on May the 5th.

Covid-19 was diagnosed by RT-PCR in 93.3% of cases. A total of 67 patients were admitted to hospital and 37 were managed at home, including all children (Table 1). Main indications for adult LT were alcohol-related liver disease (40/91) and hepatitis C (18/91). In brief, adult patients managed at home consisted of younger patients, with lower BMI (and also a trend to lower rate of diabetes) and with a lower frequency of dyspnea, fever, and cough (Table 2). Immunosuppressive treatment was not modified for patients managed at home. Hospitalized patients had a median age of 65.2 years (IQR: 58.1 – 73.2 years) and two thirds were men. Most of them were overweight (67.3%) and the most common comorbidities included hypertension (61.2%), diabetes (50.7%), cardiovascular disease (20.9%) and history of respiratory disease (16.4%). Last available liver function tests before SARS-CoV-2 infection (median delay 5.6 months) were within normal ranges in the vast majority of cases (75/91). SARS-CoV-2 infection was identified after a median of 92.8 months (IQR: 40.1 – 194.7 months) from LT. The median delay between the onset of symptoms and hospital admission was 6 days (IQR: 3 – 9 days). The most frequent symptom was fever (70.1%), followed by cough (64.2%) and dyspnea (62.7%). At admission, available median levels of C-reactive protein (CRP) and procalcitonin were 70 mg/L and 0.26 ng/mL, respectively (Table 3). The median lymphocyte count was 0.70 × 10^9/L. Lung infiltrates on chest CT images were detected in all cases. Liver enzymes (defined as more than 2 upper normal or basal values during hospitalization) deteriorated in 11/67 hospitalized patients (16.4%).

Management of immunosuppression

On admission, calcineurin inhibitors (CNIs), antimetabolites, mTOR inhibitor and steroids were being taken by 92.2%, 64.2%, 14.9% and 22.4% of patients, respectively (Table 2). During hospitalization, antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively (Table 3). No liver biopsy was performed. No case of biopsy proven rejection or graft lost (excepting patients who died) occurred.

Treatment and outcome

Most patients received nasal oxygen therapy (59.7%). Antibiotics were given for preventive or curative purpose. From the 20 hospitalized patients with recognize superinfection (29.9%), it included 18 cases of pulmonary superinfection, and it included 17 cases of bacterial infections, 2 cases of fungal infection and one combined. Antibiotics other than azithromycin were given to 59.7% of the patients; hydroxychloroquine and azithromycin were given to 20.9% and 23.9% of the patients, respectively. Antiviral drugs and tocilizumab were administered to only 4 (6.0%) and 1 (1.5%) cases, respectively. MV was required for 25.4% of patients. Acute kidney injury occurred in 47.8% of patients, with renal replacement therapy being necessary in third of cases. Considering all adult patients, the composite endpoint of severe Covid-18 within 30 days of diagnosis was reached by 33.0% of the adult patients (Fig. 1A). The composite endpoint of severe Covid-19 within 30 days of hospital admission was reached by 44.8% of the patients (Fig. 1B). The 30-day mor-
Table 1  Characteristics of children LT recipients.

| Characteristics                          | Children recipients | N  |
|------------------------------------------|---------------------|----|
| **Baseline characteristics**             |                     |    |
| Median age [IQR] - yr                    | 13.0 [7.4–14.2]     | 13 |
| Age > 65 yr - no. (%): N                 | 13 (100.0%)         | 13 |
| Male, n (%)                              | 5 (38.5%)           | 13 |
| Median BMI [IQR] - kg/m²                 | 19.4 [17.0–20.6]    | 11 |
| Blood group, n (%):                      |                     |    |
| A                                        | 4 (30.8%)           | 13 |
| AB                                       | 2 (15.4%)           | 13 |
| B                                        | 1 (7.7%)            | 13 |
| O                                        | 6 (46.2%)           | 13 |
| Transplanted organ, n (%):               |                     |    |
| Liver                                    | 12 (92.3%)          | 13 |
| Liver-Kidney                             | 1 (7.7%)            | 13 |
| Retransplantation, n (%)                 | (0.0%)              | 13 |
| Living donor, n (%)                      | 3 (23.1%)           | 13 |
| Time Tx to COVID [IQR] - mo              | 9.2 [5.4–86.8]      | 13 |
| Tx within 1 yr - no. (%)                 | 7 (53.8%)           | 13 |
| Hypertension, n (%)                      | 1 (7.7%)            | 13 |
| Cardiovascular disease, n (%)            | 0 (0.0%)            | 13 |
| Ischemic disease, n (%)                  | 0 (0.0%)            | 13 |
| Respiratory disease, n (%)               | (0.0%)              | 13 |
| Diabetes, n (%)                          | 3 (23.1%)           | 13 |
| Cancer, n (%)                            | 1 (7.7%)            | 13 |
| Median baseline Scr [IQR] - μmol/l       | 46.0 [36.0–54.5]    | 11 |
| RAS blockers, n (%)                      | 1 (7.7%)            | 13 |
| Statin, n (%)                            | (0.0%)              | 13 |
| **Baseline immunosuppression**           |                     |    |
| Induction, n (%):                        |                     | 13 |
| No induction                             | 3 (23.1%)           | 13 |
| anti-IL2R                                | 10 (76.9%)          | 13 |
| CNI, n (%): Tacrofilimus                 | 13 (100.0%)         | 13 |
| Mycophenolate, n (%)                     | 6 (46.2%)           | 13 |
| Azathioprin, n (%)                       | 0 (0.0%)            | 13 |
| mTOR inhibitor, n (%)                    | 1 (7.7%)            | 13 |
| Steroids, n (%)                          | 4 (30.8%)           | 13 |
| **Clinical data**                        |                     |    |
| Cough, n (%)                             | 7 (53.8%)           | 13 |
| Rhinitis, n (%)                          | 3 (23.1%)           | 13 |
| Dyspnea, n (%)                           | 5 (38.5%)           | 13 |
| Anosmia, n (%)                           | 2 (15.4%)           | 13 |
| Fever, n (%)                             | 4 (30.8%)           | 13 |
| Headache, n (%)                          | 3 (23.1%)           | 13 |
| Diarrhea, n (%)                          | 2 (15.4%)           | 13 |
| Vomiting, n (%)                          | 2 (15.4%)           | 13 |
| Myalgia, n (%)                           | 2 (15.4%)           | 13 |
| Neurological signs, n (%)                | (0.0%)              | 13 |
| Cutaneous lesions, n (%)                 | 1 (7.7%)            | 13 |
| **Biological data**                      |                     |    |
| Median CRP [IQR] - mg/l                  | 15 [8–26]           | 6  |
| Median procalcitonin [IQR] - ng/mL       | 10.37 [5.56–15.19]  | 2  |
| Median lymphocyte count [IQR] - G/l       | 0.97 [0.90–1.44]    | 5  |
| Median platelet count [IQR] - G/l         | 180 [179–182]       | 5  |
| Median SaO2 [IQR] - %                     | 99 [99–100]         | 5  |
| Median admission Scr [IQR] - μmol/l       | 66 [56–78]          | 4  |
Table 2  Comparison of home-managed and In-hospital adult LT recipients.

|                               | All cohort N = 91 | Home N = 24 | In-hospital N = 67 | p | N |
|-------------------------------|-------------------|-------------|-------------------|---|---|
| **Baseline characteristics**  |                   |             |                   |   |   |
| Median age [IQR] - yr         | 64.4 [54.9–71.3]  | 58.5 [46.3–65.0] | 65.2 [58.1–73.2]  | 0.002 | 91 |
| Age > 65 yr - n (%)           | 40 (44.0%)        | 6 (25.0%)   | 34 (50.7%)        | 0.052 | 91 |
| Male, n (%)                   | 64 (70.3%)        | 18 (75.0%)  | 46 (68.7%)        | 0.746 | 91 |
| Median BMI [IQR] - kg/m²      | 26.0 [23.2–29.7]  | 23.4 [20.5–27.5] | 26.4 [23.8–31.0] | 0.021 | 71 |
| BMI > 25 kg/m² - n (%)        | 44 (62.0%)        | 9 (47.4%)   | 35 (67.3%)        | 0.209 | 71 |
| Blood group, n (%):           |                   |             |                   |   |   |
| A                             | 26 (41.3%)        | 10 (55.6%)  | 16 (35.6%)        | 0.155 | 63 |
| AB                            | 2 (3.2%)          | 1 (5.6%)    | 1 (2.2%)          |       |   |
| B                             | 5 (7.9%)          | 2 (11.1%)   | 3 (6.7%)          |       |   |
| O                             | 30 (47.6%)        | 5 (27.8%)   | 25 (55.6%)        |       |   |
| Transplanted organ, n (%):    |                   |             |                   | 0.316 | 91 |
| Liver                         | 78 (85.7%)        | 23 (95.8%)  | 55 (82.1%)        |       |   |
| Liver-Heart                   | 1 (1.1%)          | 0 (0.0%)    | 1 (1.5%)          |       |   |
| Liver-Kidney                  | 12 (13.2%)        | 1 (4.2%)    | 11 (16.4%)        |       |   |
| Retransplantation, n (%)      | 4 (5.2%)          | 2 (8.7%)    | 2 (3.7%)          | 0.578 | 77 |
| Time Tx to COVID [IQR] - mo   | 84.9 [34.0–168.4] | 57.0 [24.5–119.8] | 92.8 [40.1–194.7] | 0.084 | 90 |
| Tx within 1yr - n (%)         | 10 (11.1%)        | 3 (12.5%)   | 7 (10.6%)         | 0.723 | 90 |
| Hypertension, n (%)           | 51 (56.0%)        | 10 (41.7%)  | 41 (61.2%)        | 0.157 | 91 |
| Cardiovascular disease, n (%) | 19 (20.9%)        | 5 (20.8%)   | 14 (20.9%)        | 1.000 | 91 |
| Ischemic disease, n (%)       | 13 (14.3%)        | 3 (12.5%)   | 10 (14.9%)        | 1.000 | 91 |
| Respiratory disease, n (%)    | 13 (14.3%)        | 2 (8.3%)    | 11 (16.4%)        | 0.501 | 91 |
| Diabetes, n (%)               | 40 (44.0%)        | 6 (25.0%)   | 34 (50.7%)        | 0.052 | 91 |
| Cancer, n (%)                 | 19 (20.9%)        | 4 (16.7%)   | 15 (22.4%)        | 0.765 | 91 |
| Median baseline SCr [IQR] - μmol/l | 103.0 [80.0–135.0] | 100.0 [76.0–123.5] | 107.5 [85.5–141.5] | 0.268 | 69 |
| Baseline SCr > 115 μmol/l, n (%) | 28 (40.6%) | 6 (31.6%) | 22 (44.0%) | 0.507 | 69 |
| Smoking, n (%)                | 13 (14.3%)        | 3 (12.5%)   | 10 (14.9%)        | 1.000 | 91 |
| RAS blockers, n (%)           | 24 (26.4%)        | 3 (12.5%)   | 21 (31.3%)        | 0.127 | 91 |
| Statin, n (%)                 | 22 (24.2%)        | 3 (12.5%)   | 19 (28.4%)        | 0.201 | 91 |
| **Baseline immunosuppression**|                   |             |                   | 1.000 | 90 |
| CNI, n (%)                    |                   |             |                   |       |   |
| No CNI                        | 14 (15.6%)        | 4 (16.7%)   | 10 (15.2%)        |       |   |
| Tacrolimus                    | 70 (77.8%)        | 19 (79.2%)  | 51 (77.3%)        |       |   |
| Cyclosporine                  | 6 (6.7%)          | 1 (4.2%)    | 5 (7.6%)          |       |   |
| Mycophenolate, n (%)          | 53 (58.2%)        | 13 (54.2%)  | 40 (59.7%)        | 0.818 | 91 |
| Azathioprin, n (%)            | 3 (3.3%)          | 0 (0.0%)    | 3 (4.5%)          | 0.563 | 91 |
| mTOR Inhibitor, n (%)         | 14 (15.4%)        | 4 (16.7%)   | 10 (14.9%)        | 1.000 | 91 |
| Steroids, n (%)               | 16 (17.6%)        | 1 (4.2%)    | 15 (22.4%)        | 0.060 | 91 |
| Belatacept, n (%)             | 2 (2.2%)          | 0 (0.0%)    | 2 (3.0%)          | 1.000 | 91 |
| **Clinical symptoms**         |                   |             |                   |       |   |
| Cough, n (%)                  | 51 (56.0%)        | 8 (33.3%)   | 43 (64.2%)        | 0.018 | 91 |
| Rhinitis, n (%)               | 13 (14.3%)        | 5 (20.8%)   | 8 (11.9%)         | 0.316 | 91 |
| Dyspnea, n (%)                | 45 (49.5%)        | 13 (52.0%)  | 42 (62.7%)        | <0.001 | 91 |
| Anosmia, n (%)                | 9 (9.9%)          | 3 (12.5%)   | 6 (9.0%)          | 0.694 | 91 |
| Fever, n (%)                  | 55 (60.4%)        | 8 (33.3%)   | 47 (70.1%)        | 0.003 | 91 |
| Headache, n (%)               | 20 (22.0%)        | 6 (25.0%)   | 14 (20.9%)        | 0.897 | 91 |
| Diarrhea, n (%)               | 19 (20.9%)        | 2 (8.3%)    | 17 (25.4%)        | 0.142 | 91 |
| Vomiting, n (%)               | 6 (6.6%)          | 2 (8.3%)    | 4 (6.0%)          | 0.652 | 91 |
| Myalgia, n (%)                | 28 (30.8%)        | 6 (25.0%)   | 22 (32.8%)        | 0.648 | 91 |
| Neurologic signs, n (%)       | 9 (9.9%)          | 1 (4.2%)    | 8 (11.9%)         | 0.436 | 91 |
| Cutaneous lesions, n (%)      | 4 (4.4%)          | 0 (0.0%)    | 4 (6.0%)          | 0.570 | 91 |

Abbreviations: IQR, interquartile range; BMI, body mass index; Ref, reference; Txtransplantation; RAS, renin-angiotensin system; CNI, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.
tality rate of all adult patients was 20.0% (Fig. 1C). The 30-day mortality rate of hospitalized patients was 28.1% (Fig. 1D).

Risk factors for severe Covid-19

Table 4 compares the general characteristics of patients who developed severe Covid-19 (n = 33) versus those who did not (n = 58). Age, dyspnea, fever, CRP level, lymphocyte count, a partial pressure of oxygen <95% on admission, an acute kidney injury and a moderate/severe lung involvement were significantly associated with severe Covid-19. Considering only baseline characteristics and clinical symptoms, multivariate analysis identified dyspnea and fever as independent risk factors for severe disease (Table 5).

Risk factors for mortality

Table 6 compares the general characteristics of patients who died (n = 20) versus those who did not (n = 71). Univariate analysis disclosed that age, fever, neurologic signs, and baseline serum creatinine were significantly associated with death. Considering only baseline characteristics and clinical symptoms, multivariate analysis identified only age as independent risk factor for death (there was a tendency for baseline serum creatinine without reaching statistical significance, p = 0.071) (Table 5).

**Discussion**

Despite the growing literature focusing on the clinical manifestations and prognosis of Covid-19, data on certain selected clinical populations that merit special consideration, including immunocompromised patients with a history of solid organ transplantation, remain limited. Herein we report comprehensive data on from a large cohort consisting of 104 French LT recipients with Covid-19. Since the number of alive LT French recipients was 14,948 at the 1st of January 2020 (personal communication, Corinne Antoine, Agence de
la Biomédicine), the incidence of Covid-19 in LT recipients was 0.7%, but was probably underestimated.

First, and unsurprisingly, we observed that the clinical presentation of Covid-19 in LT recipients is similar to that reported in the general population, with fever and cough being the two more common symptoms. These findings are in line with those from initial large reports showing fever in 77 – 94% and cough in 68 – 79% of cases, respectively [12–14]. Interestingly, anosmia, which is highly suggestive but was not reported in initial series because it was not identified as a Covid-19-related symptom, was present in almost 10% of our patients. We also report here that some immunocompromised patients with Covid-19 were manageable at home. This decision was taken on a case-basis and was chiefly implemented for younger patients without dyspnea and high fever, which were significant predictors of severe disease in our population. This patient subgroup was offered teleconsultation or phone call surveillance until disease resolution. We hypothesize that some LT recipients who presented Covid-19 and stay at home were not identified by now, and therefore not included in our cohort. On the opposite, we are confident that almost all French LT recipients hospitalized were included in the present report.

The initially reported mortality rate for Covid-19 in the general population of Wuhan, China, was 1.4% [12]. Mortality dramatically increased for hospitalized patients (10%) [14] and moreover for patients admitted to ICU (26%). [15] Early data from small-sized series of transplanted patients reported one death out of 15 patients [16] five out of 25 [17], and ten out of 36 patients [18]. More recently, Pereira and coll. reported their initial experience with 90 solid organ transplant recipients (including 13 LT recipients) from two centers during the first 3 weeks of the outbreak in New York City. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) [5]. Focusing on LT recipients, Webb and coll. reported details of 39 LT recipients who developed COVID-19 worldwide, including nine (23%) who died from respiratory failure [11]. According to the European Liver Transplant registry, from the first 103 COVID-19 cases observed between March 1, and April 24, 2020, mainly from centers located in specific areas of Italy, Spain, and France (including some French patients reported here), after a median follow-up of 18 days, 16 patients (15.5%) had died [10]. When considering only patients requiring mechanical ventilation, the mortality rate increased to 44.4%. Bocchetti and coll. reported data on a 57 LT recipients European cohort, 41 (71.9%) patients were hospitalized and 11 (19.3%) developed acute respiratory distress syndrome [19]. Estimated mortality rate was 12% (95%CI 5% to 24%), which increased to 17% (95%CI 7%–32%) among hospitalized patients. From the 38 LT recipients described by Lee and coll., seven died (18% overall, 29% hospitalized) [20]. Herein, the 30-day mortality rate of our hospitalized LT recipients with Covid-19 was 28.1%, but it must be pointed that our follow-up was longer. MV was required in 25.4% of our hospitalized patients, recalling what has been reported for immunocompetent subjects (16 – 33%) [13,14]. Rabie and coll. conducted a multicenter comparative study in the

![Figure 1](image-url)  
**Figure 1** Outcome of 91 adult LT recipients with Covid-19.  
A. Probability of reaching the composite endpoint of severe disease (ICU admission or mechanical ventilation or death) in LT adult recipients with Covid-19. The cumulative incidence for the composite endpoint at day-30 was 33.0% (22.6–42.0).  
B. Probability of reaching the composite endpoint of severe disease (ICU admission or mechanical ventilation or death) in LT adult recipients who were hospitalized with Covid-19. The cumulative incidence for the composite endpoint at day-30 was 44.8% (31.5–55.5).  
C. Kaplan–Meier plot of survival in adult LT recipients with Covid-19. The 30-day survival rate after diagnosis was 80.0% (71.8–89.0).  
D. Kaplan–Meier plot of survival in adult LT recipients who were hospitalized with Covid-19. The 30-day survival rate after diagnosis was 71.9% (61.3–84.3).
Table 4  Risk factors for ICU admission or mechanical ventilation or death (univariate).

| Baseline characteristics | No event | Event | HR       | p.ratio | N  |
|--------------------------|----------|-------|----------|---------|----|
| Median age [IQR] - yr    | 62.0 [52.9–68.9] | 65.8 [60.3–73.2] | 1.04 [1.00;1.07] | 0.029 | 91 |
| Age > 65 yr - n (%)      | 22 (37.9%) | 18 (54.5%) | 1.66 [0.84;3.29] | 0.148 | 91 |
| Male, n (%)              | 39 (67.2%) | 25 (75.8%) | 1.45 [0.65;3.21] | 0.364 | 91 |
| Median BMI [IQR] - kg/m² | 25.0 [22.0–28.9] | 27.0 [24.8–31.0] | 1.04 [0.98;1.10] | 0.220 | 71 |
| BMI > 25 kg/m² - n (%)   | 23 (53.5%) | 21 (75.0%) | 2.07 [0.88;4.89] | 0.096 | 71 |
| Blood group, n (%):      |          |       |          |        |    |
| A                        | 18 (45.0%) | 8 (34.8%) | Ref.     |       |    |
| AB                       | 2 (5.00%)  | 0 (0.00%) | Ref.     |       |    |
| B                        | 3 (7.50%)  | 2 (8.70%) | 1.47 [0.31;6.90] | 0.629 |    |
| O                        | 17 (42.5%) | 13 (56.5%) | 1.42 [0.59;3.42] | 0.437 |    |
| Time Tx to COVID [IQR] - mo | 76.1 [26.6–163] | 89.3 [48.0–183] | 1.00 [1.00;1.01] | 0.277 | 90 |
| Tx within 1 yr - n (%)   | 6 (10.5%)  | 4 (12.1%) | 1.24 [0.43;3.52] | 0.692 | 90 |
| Hypertension, n (%)      | 33 (56.9%) | 18 (45.4%) | 0.93 [0.47;1.84] | 0.831 | 91 |
| Cardiovascular disease, n (%)   | 13 (22.4%) | 6 (18.2%) | 0.82 [0.34;1.99] | 0.660 | 91 |
| Ischemic disease, n (%)   | 8 (13.8%)  | 5 (15.2%) | 1.13 [0.44;2.93] | 0.799 | 91 |
| Respiratory disease, n (%) | 7 (12.1%)  | 6 (18.2%) | 1.26 [0.52;3.06] | 0.606 | 91 |
| Diabetes, n (%)           | 22 (37.9%) | 18 (54.5%) | 1.72 [0.87;3.42] | 0.121 | 91 |
| Cancer, n (%)             | 9 (15.5%)  | 10 (30.3%) | 2.09 [0.99;4.40] | 0.052 | 91 |
| Median baseline Scr [IQR] - μmol/l | 100 [80.0–128] | 105 [88.5–140] | 1.00 [1.00;1.01] | 0.386 | 69 |
| Baseline Scr >115 μmol/l, n (%) | 19 (31.3%) | 2 (39.1%) | 0.93 [0.40;2.15] | 0.864 | 69 |
| Smoking, n (%)            | 7 (12.1%)  | 6 (18.2%) | 1.62 [0.67;3.93] | 0.284 | 91 |
| RAS blockers, n (%)       | 16 (27.6%) | 8 (24.2%) | 0.82 [0.37;1.82] | 0.626 | 91 |
| Statin, n (%)             | 17 (29.3%) | 5 (15.2%) | 0.48 [0.19;1.25] | 0.133 | 91 |
| CNI, n (%)                | 50 (86.2%) | 26 (81.2%) | 0.74 [0.31;1.81] | 0.515 | 90 |
| Mycophenolate, n (%)      | 34 (58.6%) | 19 (57.6%) | 1.00 [0.50;1.99] | 0.992 | 91 |
| Azathioprin, n (%)        | 3 (5.17%)  | 0 (0.00%) | 0.00 [0.00;.] | 0.997 | 91 |
| mTOR inhibitor, n (%)     | 8 (13.8%)  | 6 (18.2%) | 1.23 [0.51;2.99] | 0.643 | 91 |
| Steroids, n (%)           | 9 (15.5%)  | 7 (21.2%) | 1.46 [0.63;3.36] | 0.378 | 91 |
| Clinical symptoms         |          |       |          |        |    |
| Cough, n (%)              | 31 (53.4%) | 20 (60.6%) | 1.27 [0.63;2.56] | 0.499 | 91 |
| Rhinitis, n (%)           | 9 (15.5%)  | 4 (12.1%) | 0.80 [0.28;2.29] | 0.681 | 91 |
| Dyspnea, n (%)            | 22 (37.9%) | 23 (69.7%) | 3.01 [1.43;6.33] | 0.004 | 91 |
| Anosmia, n (%)            | 7 (12.1%)  | 2 (6.06%) | 0.52 [0.12;2.18] | 0.371 | 91 |
| Fever, n (%)              | 29 (50.0%) | 26 (78.8%) | 3.10 [1.34;7.15] | 0.008 | 91 |
| Headache, n (%)           | 11 (19.0%) | 9 (27.3%) | 1.39 [0.64;2.98] | 0.404 | 91 |
| Diarrhea, n (%)           | 14 (24.1%) | 5 (15.2%) | 0.60 [0.23;1.56] | 0.299 | 91 |
| Vomiting, n (%)           | 6 (10.3%)  | 0 (0.00%) | 0.00 [0.00;.] | 0.997 | 91 |
| Myalgia, n (%)            | 17 (29.3%) | 11 (33.3%) | 1.15 [0.56;2.37] | 0.707 | 91 |
| Neurologic signs, n (%)   | 4 (6.90%)  | 5 (15.2%) | 2.15 [0.83;5.59] | 0.116 | 91 |
| Cutaneous lesions, n (%)  | 1 (1.72%)  | 3 (9.09%) | 2.85 [0.87;9.35] | 0.085 | 91 |
| Admission characteristics* |         |       |          |        |    |
| CRP >70 mg/l–n (%)        | 10 (31.2%) | 13 (59.1%) | 2.49 [1.06;5.85] | 0.037 | 54 |
| Procalcitonin >0.2 ng/mL – n (%) | 8 (61.5%) | 6 (54.5%) | 0.94 [0.29;3.09] | 0.924 | 24 |
| Median lymphocyte count [IQR] - G/l | 0.88 [0.72–1.16] | 0.62 [0.46–0.85] | 0.25 [0.07;0.89] | 0.033 | 49 |
| Thrombocytopenia <150 G/l–n (%) | 13 (36.1%) | 8 (40.0%) | 1.18 [0.48;2.89] | 0.718 | 56 |
| SaO2 < 95% - n (%)        | 5 (15.2%)  | 14 (50.0%) | 3.30 [1.57;6.96] | 0.002 | 61 |
| Admission Scr >115 μmol/l, n (%) | 13 (37.1%) | 13 (76.5%) | 4.48 [1.46;13.8] | 0.009 | 52 |
| Lung CT scan, n (%):      |          |       |          |        |    |
| mild                     | 17 (65.4%) | 6 (27.3%) | Ref.     |       |    |
| moderate                 | 7 (26.9%)  | 10 (45.5%) | 3.29 [1.19;9.09] | 0.021 |    |
| severe                   | 2 (7.69%)  | 6 (27.3%) | 5.16 [1.63;16.3] | 0.005 |    |

Abbreviations: IQR, interquartile range; CRP, C-reactive protein; SaO2, arterial oxygen saturation; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.

* Available only for in-hospital patients.
US including 112 adult LT recipients with COVID-19 [21]. The mortality rate was 22.3%; 72.3% were hospitalized and 26.8% admitted to the ICU. Compared to age and gender matched non-transplant patients with chronic liver disease and COVID-19 (n = 375), the incidence of acute liver injury was lower in LT recipients but liver injury was significantly associated with mortality and ICU admission in LT recipients. Diabetes was also associated with mortality in LT recipients.

We aimed to identify risk factors for severe disease (composite endpoint including need for ICU, need for mechanical ventilation, or death) and death. Fever and dyspnea are probably clinical features of severe disease instead of risk factors. First of all, age had a significant impact on severity of the disease and mortality, as observed in general population [13]. Male gender has been previously linked to severe Covid-19 [22]; it was not in our cohort, but males represented the vast majority of our cases. Similarly, the association between overweight/obesity and severe Covid-19 was not demonstrated in our cohort, whereas it has been shown in the general population (BMI ≥ 30 kg/m²) [14] but also in French kidney transplant recipients from our SOT COVID registry (BMI ≥ 25 kg/m²) [23]. Biological markers of severe inflammation were available only for hospitalized patients and were associated with severe disease (univariate analysis). Previous studies reported that procalcitonin and CRP levels were higher in patients requiring MV and that procalcitonin levels were an unfavorable predictor of mortality [13,14]. Similarly, previous studies reported that lymphopenia could predict severe Covid-19 or mortality [13,24]. In the solid organ transplant cohort from Pereira and coll., advanced age, hypertension and active cancer were significantly associated (univariate analysis) with severe disease [5].

A majority of our patients received antibiotics including azithromycin, whereas a minority received specific antiviral drugs. The lopinavir/ritonavir combination has strong pharmacological interactions with CNIs and mTOR inhibitors which have been largely evaluated in HIV patients [25–27]. The low usage of hydroxychloroquine may be explained by low-quality evidence on its effectiveness. The debate on the management of immunosuppression in transplant recipients following SARS-CoV-2 infection remains unresolved. In our study, baseline immunosuppressive regimen had no impact on severity of Covid-19. Although not statistically significant, time since LT seems shorter for LT recipients remaining at home that those hospitalized, pointing towards lesser importance of level of immunosuppression (as compared to other major risk factors including age, but also past duration of immunosuppression). As previously reported in solid organ transplant recipients [5,16–19,21,28–31], a reduction in maintenance immunosuppression was made in a large part of our hospitalized patients: antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively. According to the French recommendations on management of immunosuppressive (and also most recommendations for organ transplant recipients) modification (i.e. reduction) of immunosuppression was driven by Covid-19 severity [32], leading to a major bias regarding global outcome. Precise guidance on the management of immunosuppressive drugs is still lacking, and no firm conclusions can therefore be drawn on the beneficial impact of such strategy by now.

Our findings need to be interpreted in the context of some limitations. We acknowledge that some baseline clinical, laboratory, or imaging data were missing and that probably some patients who were managed at home were not captured by now. Notwithstanding the potential caveats, length of follow-up makes it possible to avoid the risk of ignoring the pejorative evolutions of certain patients (none of the patient is still on ICU at last follow-up) and therefore this study is by far the largest so far to provide a comprehensive description of LT recipients with Covid-19. Finally, in our study, we were not able to compare LT recipients and non-transplant patients, which would have been of great interest to assess whether the different outcomes are different in the LT immunosuppressed population as opposed to the general population matched by age and presence of comorbidities. We plan to do so from our global cohort of solid organ transplant recipients, and also by comparing our LT patients to the ongoing French cohort including patients with chronic liver disease built by the French society of Hepatology (AEF). Nevertheless, in the large study in UK general population, it has been reported that history of organ transplantation had a great pejorative prognostic value, together with other morbidity conditions including chronic renal failure and chronic liver disease [1].

In conclusion, our results from a large nationwide cohort confirm that Covid-19 in LT recipients portends a high risk of mortality. Proper management of immunosuppression and tailored treatment of this fragile population remain challenging, and further data on large cohorts are necessary in order to improve our level of knowledge and generate robust recommendations.

| Table 5 | Risk factors for the composite endpoint (ICU admission or mechanical ventilation or death) and death only in multivariate analysis. |
| --- | --- |
| | Composite endpoint | Death only |
| | HR [95%CI] | p | HR [95%CI] | p |
| Dyspnea | 2.39 [1.11, 5.15] | 0.026 | — | — |
| Fever | 2.40 [1.01, 5.69] | 0.047 | — | — |
| Baseline Scr (μmol/l) | — | — | 2.75 [0.92, 8.26] | 0.071 |
| Age (years) | — | — | 1.05 [1.01, 1.10] | 0.024 |
| Scr: Serum creatinine. Concordance is 0.68 for the composite endpoint model, and 0.71 for the death only model. |  |  |  |  |
Table 6  Risk factors for death (univariate).

| Baseline characteristics | No event | Event | HR | p.ratio |
|--------------------------|----------|-------|----|---------|
| **Median age [IQR] - yr** | 62.2 [53.5–69.1] | 70.4 [62.3–74.9] | 1.05 [1.01;1.10] | 0.017 |
| Age > 65 yr - n (%)       | 28 (39.4%) | 12 (60.0%) | 2.01 [0.82;4.92] | 0.126 |
| Male, n (%)               | 50 (70.4%) | 14 (70.0%) | 1.02 [0.39;2.66] | 0.966 |
| Median BMI [IQR] - kg/m²  | 25.9 [23.0–29.2] | 26.0 [23.7–30.2] | 1.01 [0.92;1.11] | 0.769 |
| BMI > 25 kg/m² - n (%)    | 35 (62.5%) | 9 (60.0%) | 0.91 [0.33;2.57] | 0.866 |
| **Blood group, n (%)**    | 23 (46.0%) | 3 (23.1%) | Ref. | Ref. |
| A                        | 2 (4.00%) | 0 (0.00%) | 0.00 [0.00; ] | 0.998 |
| AB                       | 4 (8.00%) | 1 (7.69%) | 2.01 [0.21;19.3] | 0.546 |
| O                        | 21 (42.0%) | 9 (69.2%) | 2.90 [0.78;10.7] | 0.110 |
| Time Tx to COVID [IQR] - mo | 79.2 [27.6–162] | 120 [57.6–210] | 1.00 [1.00;1.01] | 0.220 |
| Tx within 1 yr - n (%)    | 8 (11.4%) | 2 (10.0%) | 0.92 [0.21;3.96] | 0.910 |
| Hypertension, n (%)      | 43 (60.6%) | 8 (40.0%) | 0.46 [0.19;1.13] | 0.091 |
| Cardiovascular disease, n (%) | 13 (18.3%) | 6 (30.0%) | 1.74 [0.67;4.54] | 0.255 |
| Ischemic disease, n (%)  | 8 (11.3%) | 5 (25.0%) | 2.32 [0.84;6.40] | 0.104 |
| Respiratory disease, n (%) | 8 (11.3%) | 5 (25.0%) | 2.17 [0.79;5.96] | 0.134 |
| Diabetes, n (%)          | 30 (42.2%) | 10 (50.0%) | 1.31 [0.54;3.14] | 0.552 |
| Cancer, n (%)            | 13 (18.3%) | 6 (30.0%) | 1.92 [0.74;4.99] | 0.182 |
| Median baseline Scr [IQR] - μmol/l | 102 [80.0–124] | 135 [87.0–157] | 1.01 [1.00;1.01] | 0.049 |
| Baseline Scr > 115 μmol/l, n (%) | 22 (37.9%) | 6 (54.5%) | 1.82 [0.56;5.96] | 0.323 |
| Smoking, n (%)           | 9 (12.7%) | 4 (20.0%) | 1.79 [0.60;5.36] | 0.298 |
| RAS blockers, n (%)      | 19 (26.8%) | 5 (25.0%) | 0.89 [0.32;2.45] | 0.822 |
| Statin, n (%)            | 18 (25.4%) | 4 (20.0%) | 0.79 [0.26;2.36] | 0.669 |
| CNI, n (%)               | 62 (87.3%) | 14 (73.7%) | 0.45 [0.16;1.25] | 0.126 |
| Mycophenolate, n (%)     | 44 (62.0%) | 9 (45.0%) | 0.58 [0.24;1.39] | 0.222 |
| Azathioprin, n (%)       | 3 (4.23%) | 0 (0.00%) | 0.00 [0.00; ] | 0.998 |
| mTOR inhibitor, n (%)    | 9 (12.7%) | 5 (25.0%) | 1.98 [0.72;5.44] | 0.187 |
| Steroids, n (%)          | 13 (18.3%) | 3 (15.0%) | 0.84 [0.25;2.87] | 0.782 |
| **Clinical symptoms**    |         |       |    |         |
| Cough, n (%)             | 39 (54.9%) | 12 (60.0%) | 1.16 [0.48;2.84] | 0.741 |
| Rhinitis, n (%)          | 10 (14.1%) | 3 (15.0%) | 1.11 [0.33;3.80] | 0.863 |
| Dyspnea, n (%)           | 32 (45.1%) | 13 (65.0%) | 2.05 [0.82;5.13] | 0.127 |
| Anosmia, n (%)           | 8 (11.3%) | 1 (5.00%) | 0.44 [0.06;3.30] | 0.426 |
| Fever, n (%)             | 39 (54.9%) | 16 (80.0%) | 3.02 [1.01;9.03] | 0.048 |
| Headache, n (%)          | 17 (23.9%) | 3 (15.0%) | 0.57 [0.17;1.95] | 0.370 |
| Diarrhea, n (%)          | 17 (23.9%) | 2 (10.0%) | 0.38 [0.09;1.62] | 0.190 |
| Vomiting, n (%)          | 6 (8.45%) | 0 (0.00%) | 0.00 [0.00; ] | 0.998 |
| Myalgia, n (%)           | 23 (32.4%) | 5 (25.0%) | 0.70 [0.26;1.94] | 0.496 |
| Neurologic signs, n (%)  | 5 (7.04%) | 4 (20.0%) | 3.08 [1.03;9.22] | 0.045 |
| Cutaneous lesions, n (%) | 2 (2.82%) | 2 (10.0%) | 2.56 [0.59;11.1] | 0.207 |
| **Admission characteristics** | | | | |
| CRP > 70 mg/l - n (%)    | 19 (43.2%) | 4 (40.0%) | 0.85 [0.24;3.01] | 0.801 |
| Procalcitonin > 0.2 ng/mL - n (%) | 12 (57.1%) | 2 (66.7%) | 1.54 [0.14;17.0] | 0.724 |
| Median lymphocyte count [IQR] - G/l | 0.85 [0.59–1.10] | 0.67 [0.56–0.90] | 0.44 [0.09;2.14] | 0.311 |
| Thrombocytopenia < 150 G/l - n (%) | 16 (34.8%) | 5 (50.0%) | 1.78 [0.52;6.16] | 0.361 |
| SaO2 < 95% - n (%)       | 12 (26.7%) | 7 (43.8%) | 2.00 [0.74;5.38] | 0.169 |
| Admission Scr > 115 μmol/l, n (%) | 21 (46.7%) | 5 (71.4%) | 2.73 [0.53;14.1] | 0.229 |
| Lung CT scan, n (%):     | 17 (47.2%) | 6 (50.0%) | Ref. | Ref. |
| Mild                     | 12 (33.3%) | 5 (41.7%) | 1.20 [0.37;3.93] | 0.764 |
| Moderate                 | 7 (19.4%) | 1 (8.33%) | 0.46 [0.06;3.85] | 0.477 |

Abbreviations: IQR, interquartile range; BMI, body mass index; Ref, reference; Tx, transplantation; RAS, renin-angiotensin system; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.

* Available only for in-hospital patients.
Authors’ contributions

Jérôme Dumortier and Marc Hazzan had full access to all the data of the cohort study and takes responsibility for the integrity of the data and the accuracy of the analyses

Conception and design: Jérôme Dumortier, Sophie Caillard, Sébastien Dharancy, Marc Hazzan, Faouzi Saliba

Acquisition, analysis and interpretation of data: Jérôme Dumortier, Christophe Duvoux, Olivier Roux, Mario Altieri, Hélène Barraud, Camille Besch, Sophie Caillard, Audrey Coilly, Filomena Conti, Sébastien Dharancy, François Durand, Claire Francoz, Florentine Garaix, Pauline Houssel-Debry, Ilias Kounis, Guillaume Lassailly, Noémie Laverdure, Vincent Leroy, Maxime Mallet, Alessandra Mazzola, Lucy Meunier, Sylvie Radenne, Jean-Philippe Richardet, Claire Vanlemmens, Marc Hazzan, Faouzi Saliba.

Drafting of the manuscript: Jérôme Dumortier, Marc Hazzan

Statistical analysis: Marc Hazzan

Critical revising the manuscript for important intellectual content: Jérôme Dumortier, Christophe Duvoux, Olivier Roux, Mario Altieri, Hélène Barraud, Camille Besch, Sophie Caillard, Audrey Coilly, Filomena Conti, Sébastien Dharancy, François Durand, Claire Francoz, Florentine Garaix, Pauline Houssel-Debry, Ilias Kounis, Guillaume Lassailly, Noémie Laverdure, Vincent Leroy, Maxime Mallet, Alessandra Mazzola, Lucy Meunier, Sylvie Radenne, Jean-Philippe Richardet, Claire Vanlemmens, Marc Hazzan, Faouzi Saliba.

Conflict of interest

None of the authors have any conflict of interest disclosures to make.

References

[1] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430–6.

[2] Ison MG, Hirsch HH. Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs. Clin Microbiol Rev 2019;32.

[3] Kumar D, Michaels MG, Morris MJ, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010;10:521–6.

[4] Kumar D, Ferreira WH, Blumberg E, Silveira F, Cordero E, Perez-Romo P, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis 2018;67:1322–9.

[5] Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–8.

[6] Bhooori S, Rossi RE, Citterio D, Mazzaferrro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol 2020;5:532–3.

[7] Gao F, Zheng KJ, Gu JY, George J, Zheng MH. COVID-19 and liver transplantation: lessons learned from three reported cases. Transpl Infect Dis 2020;e13335.

[8] Heinz N, Griesemer A, Kinney J, Vittorio J, Lagana SM, Goldner D, et al. Case of an infant with SARS-CoV-2 hepatitis early after liver transplantation. Pediatr Transplant 2020;e13778.

[9] Massoumi H, Rocco J, Frager S, Kinkhabwala M. COVID-19 infection in early post-operative period after liver transplantation. Liver Transpl 2020;26:1198–9.

[10] Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol 2020;5:724–5.

[11] Webb GJ, Moon AM, Barnes E, Barratt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020;5:643–4.

[12] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[13] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[14] Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372–4.

[15] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–81.

[16] The Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol 2020;31:1150–6.

[17] Alberici F, Delbarba E, Manenti C, Economo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020;97:1083–8.

[18] Akalin E, Azzi Y, Bartash R, Seetharamaju H, Parides M, Hengmige V, et al. Covid-19 and kidney transplantation. N Engl J Med 2020;382:2475–7.

[19] Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al. COVID-19 in an international European liver transplant recipient cohort. Gut 2020;69:1832–40.

[20] Lee BT, Perumalswami PV, Im GY, Florman S, Schiano TD. COVID-19 in liver transplant recipients: an initial experience from the U.S. Epicenter. Gastroenterology 2020;159:1176–8.

[21] Rabiee A, Sadowski B, Adeniji N, Perumalswami P, Nguyen V, Moghe A, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): US multicenter experience. Hepatology 2020.

[22] Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020;24:108.

[23] Caillard S, Angleicheau D, Malignon M, Durrbach A, Greze C, Frimat L, et al. An initial report from the French SOT COVID registry suggests high mortality due to Covid-19 in recipients of kidney transplants. Kidney Int 2020;98:1549–58.

[24] Buckner FS, McCulloch DJ, Atliur V, Blain M, McGuffin SA, Nalla AK, et al. Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis 2020;71:2167–73.

[25] Jain AB, Venkataramanan R, Eghtesad B, Marcos A, Ragni M, Shapiro R, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003;9:934–60.

[26] Meziyerv S, Zwart TC, van Etten RW, Janson JA, van Gelder T, Alwayn IPJ, et al. Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant 2020;20:1896–901.

[27] Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease inhibitor lopinavir/ritonavir
in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939–44.

[28] Lubetzky M, Aull MJ, Craig-Schapiro R, Lee JR, Marku-Podvorica J, Salinas T, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. Nephrol Dial Transplant 2020;35:1250–61.

[29] Fernandez-Ruiz M, Andres A, Loinaz C, Delgado JF, Lopez-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020;20:1849–58.

[30] Cravedi P, Suraj SM, Azzi Y, Haverly M, Farouk S, Perez-Saez MJ, et al. COVID-19 and kidney transplantation: results from the TANGO international transplant consortium. Am J Transplant 2020;20:3140–8.

[31] Zhong Z, Zhang Q, Xia H, Wang A, Liang W, Zhou W, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant 2020;20:1916–21.

[32] Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 2020;72:287–304.